It has been over 50 years since a review has focused exclusively on the monoamine oxidase (MAO) inhibitor tranylcypromine (TCP). A new review has therefore been conducted for TCP in two parts which are written to be read preferably in close conjunction: Part I -pharmacodynamics, pharmacokinetics, drug interactions, toxicology; and Part II -clinical studies with meta-analysis of controlled studies in depression, practice of TCP treatment, place in therapy. Pharmacological data of this review part I characterize TCP as an irreversible and nonselective MAO-A/B inhibitor at low therapeutic doses of 20 mg/day with supplementary norepinephrine reuptake inhibition at higher doses of 40-60 mg/day. Serotonin, norepinephrine, dopamine, and trace amines, such as the "endogenous amphetamine" phenylethylamine, are increased in brain, which leads to changes in neuroplasticity by e.g. increased neurotrophic growth factors and translates to reduced stressinduced hypersecretion of corticotropin releasing factor (CRF) and positive testing in animal studies of depression. TCP has a pharmacokinetic half-life (t 1/2 ) of only 2 h which is considerably lower than for most other antidepressant drugs. However, a very long pharmacodynamic half-life of about one week is found because of the irreversible MAO inhibition. New studies show that, except for cytochrome P450 (CYP) 2A6, no other drug metabolizing CYP-enzymes are inhibited by TCP at therapeutic doses which defines a low potential of pharmacokinetic interactions in the direction from TCP to other drugs. Insufficient information is available, however, for plasma concentrations of TCP influenced by comedication. More quantitative data are also needed for TCP metabolites such as p-hydroxytranylcypromine and N-acetyltranylcypromine. Pharmacodynamic drug interactions comprise for instance severe serotonin toxicity (SST) with serotonergic drugs and hypertensive crisis with indirect sympathomimetics. Because of the risk of severe food interaction, TCP treatment remains beset with the need for a mandatory tyramine-restricted diet. Toxicity in overdose is similar to amitriptyline and imipramine according to the distance of therapeutic to toxic doses. In conclusion, TCP is characterized by an exceptional pharmacology which is different 
Introduction
The pharmacology of the antidepressant drug tranylcypromine (trans-2-phenylcyclopropylamine, TCP) makes it an exceptional member among not only all antidepressants, but also among the pharmacological group of monoamine oxidase (MAO) inhibitors. Nevertheless, only three elementary groups (benzene ring, cyclopropane ring, and an amino group) are combined in a rather unpretentious molecule (Figure 1) . TCP was first synthesized in the 1940s as an amphetamine analogue (Burger and Yost, 1948) , but was not further investigated for the next 10 years due to low amphetamine-like activity. Retesting it as a MAO inhibitor revealed high activity against this new target (Maas and Nimmo, 1959) and led to more studies in animals (Tedeschi et al., 1959) and humans. TCP was therefore one of the earliest representatives of modern psychopharmacology. The first clinical study using TCP was published also in 1959 and reported results from 52 female patients with "affective depression of various types" who received 30-40 mg/day TCP (21 recovered, 15 much improved) (Petersen and McBrayer, 1959) . A hopeful and successful introduction to antidepressant therapy in 1962 was followed by a crash because of a, now, well-known interaction with tyramine rich food. As a result, a mandatory tyramine-reduced diet was implemented in patients treated with TCP after initially being withdrawn in the USA for some months in 1964. Clinical applications of TCP never again reached high levels and it steadily declined as additional antidepressants were introduced after the 1980s. Today, in contrast to other antidepressant MAO inhibitors, TCP is available in both the USA and Europe. However, it is also the sole irreversible MAO inhibitor marketed in many European countries, and in others no such drug is currently available. Despite this rather unusual history and distribution, TCP is still investigated in non-clinical and clinical studies of depression. Moreover, TCP has served as a scaffold for new TCPderivatives, and a lysine-specific demethylase 1 (LSD1) inhibitor activity has attracted strong interest recently outside the area of central nervous system (CNS) disorders (Binda et al., 2010) . It may be concluded that TCP is still in the minds of scientists and therapists leading to considerable progress in the future. Nevertheless, no special reviews have been published on TCP since 1965 (Atkinson and Ditman, 1965) despite several reviews on MAO inhibitors used in the treatment of psychiatric disorders in general (Cole and Bodkin, 2002; Fiedorowicz and Swartz, 2004; Gillman, 2011; Krishnan, 2007; Laux et al., 1995; Schwartz, 2013; Shulman et al., 2013; Thase et al., 1995) . We undertook a review of preclinical and clinical data of TCP with focus to modern literature including some interesting historic perspectives. This part I summarizes the underlying pharmacology, i.e. pharmacodynamics, pharmacokinetics, drug and food interactions, and toxicology of TCP. The results of clinical research and published clinical experience are reviewed in Part II, which also comprises a meta-analysis of controlled studies of TCP in depression.
Experimental procedures
A search in PubMed with the term tranylcypromine and additional terms reflecting the selected key concepts has been conducted. The terms monoamine oxidase, phenelzine and moclobemide have been used instead of tranylcypromine for concepts concerning general research questions on MAO or for concepts including comparison of TCP with other MAO inhibitors. After this screening, likely relevant publications have been selected according to titles and abstracts. A conservative approach was applied for the finding and purchase of relevant original articles if the abstracts left some doubt on the content. This electronic search was completed by hand search for additional eligible publications in important reviews and research articles of a key concept. Because of the great amount of publications (42000 hits for TCP and 420.000 hits for monoamine oxidase in PubMed) and limits in space, the number of concepts for this review has been restricted to questions of most interest with respect to the clinical application of TCP (review Part II). Thus, the objectives of this review Part I were limited to the most accepted primary and secondary mechanisms of action translating to therapeutic activity, adverse effects and drug interactions as well as important new areas of research. Many areas of the pharmacology of TCP have been excluded which are rarely or less often encountered in the discussion of the psychopharmacological application of TCP. This applies for example to TCP studies of imidazoline binding sites, preclinical studies of activity in different organ systems, preclinical studies of general psychotropic properties, seizure models, interactions with non-CNS drugs, and the questions surrounding TCP in pregnancy. As usual for drugs marketed for a long time, preclinical data are discussed also in the perspective of clinical information and some overlapping may occur therefore in the two parts of the review concerning a key concept, however, without redundancy in the data. Publications in peer reviewed journals were regarded as valid. However, methodically incorrect studies in the perspective of technical development have been rejected. The focus was to studies after 1990. Studies conducted before 1990 have also been used if there was no other work on an objective after 1990 or if older studies provided substantial completion. An almost comprehensive presentation of published TCP data was tried in the paragraph pharmacodynamic drug interactions. A balanced evaluation and citation was used in case of controversial data and discussion in literature. to an aldehyde, oxygen is reduced to hydrogen peroxide, and ammonia is formed as a byproduct.
R-CH
A distinction is drawn between two isoforms of MAO, MAO-A and MAO-B, which display different substrate and inhibitor specificity as well as different distribution in organs and tissues. Bound to the outer membrane of mitochondria in all tissues, human gut MAO is preferably MAO-A (up to 80%), and human brain (basal ganglia) and platelets contain more MAO-B (480% and 495%, respectively). However, monoamine metabolism in nerve terminals preferably operates with MAO-A. The MAO content of human liver is similar for both isoenzymes (Gerlach and Riederer, 2002; Krishnan, 2007) . Neurotransmitter levels in brain as regulated by MAO are preferred substrates of MAO-A (serotonin, norepinephrine), of MAO-B (phenylethylamine) or both (dopamine). However, the tissue distribution of MAO isoforms adds to their functional specificity in that e.g. MAO-B is the only MAO existing in basal ganglia for the metabolism of dopamine. Selective MAO-B inhibitors such as selegiline and rasagiline are therefore sufficient to increase dopamine in basal ganglia (treatment of Parkinson's disease), and selective MAO-A inhibitors such as moclobemide are sufficient to increase serotonin and norepinephrine in nerve terminals (treatment of depression) (Krishnan, 2007; Laux et al., 1995) . Nonselective MAO-A/B inhibitors such as TCP and phenelzine are also used as antidepressants because a higher antidepressant potential has been hypothesized from preclinical data compared to selective MAO-A inhibitors (Kettler et al., 2002; Mercuri et al., 2000) which was confirmed by clinical data (see Part II of the review).
Although the role of MAO in depression was discovered serendipitously, our understanding of these mechanisms continues to increase due to new data from modern pathophysiological research studies, including molecular genetics and neuroimaging studies (Bortolato et al., 2008; Liu et al., 2016; Meyer, 2012) . For example, increased MAO-A activity in patients as measured by positron emission tomography (PET) neuroimaging was found to be associated with symptomatic traits and high-risk states of depression (Chiuccariello et al., 2014; Meyer et al., 2006) . In addition, the transcription factor R1, which controls MAO-A, was decreased in patients with major depressive disorder (Johnson et al., 2011) and a meta-analysis found that the single nucleotide polymorphism (SNP) rs1137070 of MAO-A was associated with depression (Liu et al., 2016) . A low placebo response of depression was associated with high activity MAO genes in controlled studies (Leuchter et al., 2009) , and studies that treated patients after recovery of depression found that their risk of recurrence correlated with increased activity of MAO in the brain (Meyer et al., 2009) . It was even concluded by some authors that monoamine deficiency may be primarily associated with increased MAO activity, and that changes of monoamine transporters constitute a secondary pathophysiological mechanism. Inhibition of MAO activity is therefore regarded as an important target in the treatment of depressive disorders (Kersting et al., 2008 , Meyer, 2012 Schwartz, 2013) .
Examining the MAO enzyme in more detail, it is described as a mitochondrial flavoprotein with an active flavin adenine dinucleotide (FAD) moiety which acts as a redox cofactor and which is located within a hydrophobic active-site cavity formed by the folded chain of 520 amino acids (e.g., in case of MAO-B) . A large body of previous work has focused on the biochemistry and molecular biology of MAO, which is not the aim of this review. However, some central terms, such as "entrance cavity", "substrate cavity", with a "gate" between them and a "gating switch" before the entrance as well as "bent and non-planar conformation" of the tricyclic FAD may provide some insight into this complex and very interesting work. After passing the entry point of the MAO macromolecule, TCP moves a distance of 20 Å to the FAD and forms a covalent bond to a special carbon atom C4a of FAD by opening its strained cyclopropyl ring, but not to the nitrogen N5, which is the mechanism used by other MAO inhibitors. The narrow cyclopropyl ring of TCP appears like a strained trap that presents an amino group as a small kickshaw. This ring snaps open and traps the MAO. The formation of a covalent bond means that this is an irreversible reaction and that the MAO molecule, without repair, will never again catalyze an amine's oxidation (Binda et al., 2011; Edmondson et al., 2004) .
3.1.2. Irreversible MAO inhibition by TCP TCP deactivates both MAO isoforms MAO-A and MAO-B with 50% inhibition constants (IC 50 ) of 76 nM (MAO-A) and 90 nM (MAO-B), respectively, in rat brain homogenates (Coutts et al., 1987) . Studies with comparable experimental conditions provided very similar results and offered also a direct comparison with other MAO inhibitors (Table 1) (Figure 2 ). Human in-vitro platelet MAO-B activity was inhibited by TCP with IC 50 = 450 nM (60 ng/ml) and IC 50 = 300 nM (40 ng/ml) in different studies (Fritz et al., 1983) . Time dependent inhibition of MAO has been found for TCP as a typical property of irreversible enzyme inhibition kinetics (Paech et al., 1980) . The irreversible MAO inhibition of TCP was confirmed also by in-vitro dialysis experiments. No difference of pre-and post-dialysis MAO-A/B inhibition was found for rat brain homogenates incubated with TCP and subsequently dialysed for 16 h (Da Prada et al., 1989a) . After a single oral dose of 3 mg/kg of TCP or 10 mg/kg of moclobemide in rats, ex-vivo brain MAO inhibition reached 90% within one hour; however, it recovered within 16 h for the reversible inhibitor moclobemide but remained at 80% after 24 h for the irreversible inhibitor TCP despite a short pharmacokinetic half-life (Da Prada et al., 1990) . In a study of chronic TCP at doses of 1.28 mg/kg/day, rat brain MAO inhibition further increased from 86% after the first day to approximately 95% after four weeks (Hampson et al., 1988) . In humans taking a single dose of 10 mg TCP, mean platelet MAO-B inhibition reached 66% after 3 h (range 53% to 83%) and 72% after 24 h (range 57% to 87%) (Simpson et al., 1985) . In addition, a single dose of 20 mg TCP induced 85% inhibition after 24 h (Fritz et al., 1983) . Mean brain MAO-A inhibition was 58% in four healthy volunteers treated with 10 mg/day TCP for three days (Fowler et al., 1996) .
Since TCP is used as a racemic drug, it should be noted that the (+)-TCP enantiomer (1S,2R-trans-2-phenylcyclopropylamine) displays 60 times higher in-vitro MAO inhibition than the (-)-TCP enantiomer (1R,2S-trans-2-phenylcyclopropylamine). However, pharmacokinetic differences of the enantiomers yield a rat brain ex-vivo MAO inhibition of (+)-TCP that is only 10 times over (-)-TCP in single dose experiments (Fuentes et al., 1976; Hampson et al., 1986) . Mean platelet MAO-B inhibition of 90% and a lower value of 70% (po0.001) was found in 10 patients taking 5 mg/day (+)-TCP or (-)-TCP, respectively, for 3 days (Beckmann and Moises, 1983) . No difference of platelet MAO-B inhibition was found after 10 days of treatment with 30 mg/day (+)-TCP or (-)-TCP in patients because of the irreversible-mechanism based accumulation (Rüther et al., 1983) .
Changes of neurotransmitter amine levels
The substrates of MAO-A (serotonin, norepinephrine, dopamine, and tyramine) and MAO-B (dopamine, phenylethylamine, and tyramine) are increased in brain and other tissues. For example, serotonin levels are 1.4-and 2.3-fold higher after acute and chronic TCP exposure, respectively (Hampson et al., 1988) . In another ex-vivo study, rat brain serotonin increased to 3.2-fold of pretreatment values with chronic TCP administration compared to only 1.6-fold after chronic moclobemide treatment (Kettler et al., 2002) . Increased serotonin in the CNS after TCP was also confirmed in an invivo PET-study of radiotracer binding to serotonin transporter (SERT) of rats and monkeys (Lundquist et al., 2007) . Trace amines, such as phenylethylamine, may even rise over 10-fold (Hampson et al., 1988) . This may be important for TCP because the role of trace amine-associated receptors in neuropsychiatric disorders is increasingly acknowledged (Revel et al., 2012) . The oxidized neurotransmitter metabolites are decreased to approximately 30% of predose levels, including 5-hydroxyindole-3-acetic acid, 3,4-dihydroxyphenylacetic acid, and 3,4-dihydroxymandelic acid, which are metabolites of serotonin, dopamine, and norepinephrine, respectively (Da Prada et al., 1990; Greenshaw et al., 1989) . Hydrogen peroxide and hydroxyl radicals as oxidation byproducts are also decreased leading to reduced oxidative stress (Hauptmann et al., 1996) .
MAO regeneration
Regeneration of enzymes after irreversible inhibition requires de novo biosynthesis or biorepair. For MAO, this is a relative slow process that may differ according to the species, tissue, MAO isoform, and experimental conditions. Biorepair of the MAO enzyme may also be different depending on the irreversible inhibitor used, including TCP enantiomers. MAO-B activity is restored to normal levels in human platelets 1-2 weeks after TCP treatment is terminated. However, MAO recovery in platelets is coupled to newly formed platelets and may therefore represent an insufficient model of MAO recovery in brain (Fritz et al., 1983; Simpson et al., 1985; Teychenne et al., 1975) . In animal studies of TCP treatment, rat brain MAO-A/B activity regeneration reached approximately 30-40% after two days, 50% after 3.6 days, and 90-100% after 8 days. In contrast to hydrazine MAO inhibitors, which have equal rates of MAO recovery, MAO inhibition by the non-hydrazine MAO inhibitor TCP is regenerated faster. It is concluded that regeneration of TCP-inhibited MAO may include biorepair. TCP has therefore also been labeled as irreversible MAO inhibitor with partial reversibility (Da Prada et al., 1990; Kettler et al., 2002; Planz et al., 1972) . Modern PET neuroimaging studies have shown a half-life of MAO-B recovery in human brain of 40 days after selegiline treatment and similar results for rasagiline (Fowler et al., 1994; Freedman et al., 2005) . In absence of similar data after TCP treatment, it is hypothesized that the pharmacodynamic half-life of TCP in humans exceeds the animal values of approximately one week.
Monoamine reuptake inhibition by TCP
Since TCP is labeled as a MAO inhibitor, data of amine reuptake inhibition via norepinephrine transporter (NET) are often overlooked. However, one hypothesis suggests that norepinephrine reuptake inhibition may add to the antidepressant effect of TCP Schlessinger et al., 2011) . Norepinephrine reuptake inhibition of TCP may also contribute to adverse effects, such as with the selective norepinephrine reuptake inhibitor (SNRI) reboxetine, which may induce hypertension and orthostatic dysregulation as well as increased sensitivity to indirect sympathomimetics (Schlessinger et al., 2011; Schroeder et al., 2002) . On the other hand, because norepinephrine reuptake inhibitors are also tyramine reuptake inhibitors, nonselective norepinephrine reuptake inhibitors have been shown to decrease a tyramine hypertensive reaction during Figure 2 Chemical formulas of the irreversible MAO-A/B inhibitors phenelzine and isocarboxazid and of the reversible MAO-A inhibitor moclobemide.
TCP treatment (Dostert et al., 1994; Ghose and Coppen, 1977; Pare et al., 1982) . Studies in rat brain preparations and other tissues found significant effects of TCP on norepinephrine uptake at concentrations of 1 mM (130 ng/ ml), whereas serotonin and dopamine uptake was only inhibited at concentrations of 10 mM (1.3 mg/ml). The (-)-TCP was slightly more potent in the uptake inhibition compared to ( + )-TCP Tuomisto and Smith, 1986) . In a comparative structural model study, TCP was among the high-confidence predictions of an interaction with the NET nearly identical to that of the natural substrate (Schlessinger et al., 2011) . In contrast to TCP, other MAO inhibitors do not or only very slightly influence the reuptake of monoamines in the CNS at doses close to MAO inhibition Da Prada et al., 1989b; Maxwell and White, 1978) .
3.1.6. Monoamine release by TCP Racemic TCP at a concentration of 10 mM (1.3 mg/ml) in rat brain preparations caused significant dopamine release and minimal serotonin release. A comparison of the dopamine releasing activity yielded an order of amphetamine44TCP4phenelzine, while no activity was observed for isocarboxazid and selegiline (Baker et al., 1980) . Norepinephrine release from rat brain tissues was similar for (-)-TCP and ( + )-TCP at concentrations of 10 mM and (-)-TCP was more potent than (+ )-TCP in releasing serotonin and dopamine . A summary of the TCP in-vitro activity for relevant monoamine pathways is provided in Table 2. 3.2. Effects of TCP on other enzymes 3.2.1. Semicarbazide-sensitive amine oxidases (SSAO) Enzymology of SSAOs is a developing area of research and nomenclature. SSAOs are of interest for MAO inhibitors because they catalyze the same reaction of amine oxidation as MAO, however, with very different substrate specificity according to species and tissues. The active site of SSAOs contains copper and a quinone in contrast to FAD in MAO which marks a fundamental difference. It was found that TCP did not inhibit human kidney SSAO, however, bovine and equine plasma SSAOs were inhibited by high TCP concentrations (Shepard et al., 2003) . In contrast, phenelzine as other hydrazines is a relative potent inhibitor of SSAOs with IC 50 of 1 nM and 20 nM in porcine aorta and bovine lung preparations, respectively Lizcano et al., 1996; Tipnis et al., 1992) .
SSAOs are included in one primary metabolization pathway of histamine, in addition to histamine-N-methyltransferase. MAO is involved only in the secondary step of N-methyl histamine oxidation (Maintz and Novak, 2007) . Mice treated with TCP or phenelzine had increased histamine and N-methyl histamine in brain after intracerebral injection of 14 Chistamine. Without regard to SSAOs, the authors explained this by MAO inhibition of N-methyl histamine oxidation and subsequent inhibition of histamine-N-methyltransferase by increased N-methyl histamine (Schayer and Reilly, 1973) . High doses of TCP potentiated the hypotensive effect of histamine in cats which may be explained by SSAO inhibition in this experimental setting (Allen and Rand, 1969) . It is therefore not excluded that TCP may enhance the effect of dietary histamine in humans which would counteract the hypertensive reaction to tyramine (see below). More data is needed for an evaluation of the effect of dietary histamine in humans treated with TCP.
Prostacyclin synthase
TCP at concentrations of approximately 10 mM (1.3 mg/ml) inhibits prostacyclin (PGI2) synthase, which is known as a member of the cytochrome P450 (CYP) superfamily CYP8A1. Other enzymes involved in arachidonic acid metabolism and prostaglandin synthesis are also affected. Therefore, it was IC 50 50% inhibition constant, EC 50 50% effect constant, NET norepinephrine transporter, SERT serotonin transporter, DAT dopamine transporter, "r" represents less than 2-fold difference, "4" and "o" represent about 2-to 100-fold difference, "44" represents more than 100-fold difference, a IC 50 (mM) of comparator MAO inhibitor in parentheses for MAO inhibition (Da Prada et al., 1989b) and NET inhibition Da Prada et al., 1989b) , comparison of estimates of monoamine release (Baker et al.,1980; Da Prada et al., 1989b) .
b (Coutts et al., 1987) . c The IC 50 of TCP NET inhibition was 0.43 mM in the direct comparison with phenelzine in this study .
hypothesized that TCP may have anti-inflammatory activity and play a role in PGI2-mediated cardiovascular regulation and hemostasis (Frieling and Bleich, 2006; Nassar et al., 1988; Ribback et al., 2012) . However, it should be noted that plasma concentrations of TCP at therapeutic doses are far below 1.3 mg/ml.
3.2.3. Lysine-specific demethylase 1 (LSD1) Lysine-specific demethylase 1 (LSD1) is a FAD-flavoenzyme that shares a similar catalytic domain with MAO. It demethylates DNA lysine side chains, which affects the packaging of DNA in chromatin, and therefore regulates various epigenetic processes including DNA transcription, replication, and repair. Overexpression of LSD1 has been associated with cancers, endometriosis (Ding et al., 2014) , and herpes virus infection. The inhibition constant (K i ) of racemic TCP was found to be 271 mM for LSD1 compared to 16 mM of MAO-B, which indicates rather low LSD1-specificity. Using TCP as a scaffold, improved derivatives of TCP were developed with K i =1 mM for LSD1 and without MAO inhibition (Binda et al., 2010) . However, preclinical and clinical research continues with the parent TCP compound because it is already available on the market. For example, the growth of neuroblastoma cells was shown to be impaired by TCP in-vitro and tumor growth was reduced in a xenograft neuroblastoma mouse model (Schulte et al., 2009) . TCP also unlocked the alltrans-retinoic acid dependent antileukemic response in in-vitro and animal models of acute myeloid leukemia (Schenk et al., 2012) and reduced the cellular proliferation in ectopic endometrial tissue samples of endometriosis (Ding et al., 2014) . Moreover, TCP reduced herpes simplex virus 1 infections in mice, including viral reactivation in trigeminal ganglia (Yao et al., 2014) . Inhibition of LSD1 has also been discussed as a target in CNS disorders because TCP derivatives abolished long-term memory formation without affecting short-term memory in mice (Neelamegam et al., 2012) .
Drug metabolizing enzymes and pharmacokinetic drug interactions of TCP in the direction from TCP to other drugs
Early studies of pharmacokinetic interactions of TCP were beset with methodical deficiencies, such as nonspecific photometric drug assays, insufficient definition of enzyme preparations, or incorrect generalization of results of other MAO inhibitors. Although these studies were able to highlight the problem of pharmacokinetic interactions of MAO inhibitors in general, they may have been misleading in many details. Even a review from the early 1990s only cited old studies of TCP drug interactions . Therefore, in this review we included studies that used specific chromatographic methods and modern in-vitro systems of enzyme research, and only included data on TCP for the evaluation of pharmacokinetic drug interactions. TCP has been known as a CYP2C19 inhibitor in preclinical invitro tests for a long time. Unfortunately, this was extrapolated to the clinical field with levity. TCP is only a CYP2C19 inhibitor at high concentrations in human, horse, dog, and cat liver microsomes (Chauret et al., 1997) . The CYP2C19-mediated N-demethylation of doxepin and ranitidine in human liver microsomes was inhibited by TCP at high concentrations of 50 mM (6.6 mg/ml) and 250 mM (33.2 mg/ml), respectively, which is not clinically achievable even at the time of maximum plasma concentration (t max ) (Chung et al., 2000; Härtter et al., 2002) . Using cDNA-expressed human CYP enzymes, it was found that TCP is an inhibitor of CYP2D6 (K i =367 mM), CYP2C19 (K i =32 mM), and CYP2C9 (K i =56 mM). It was noted that none of these inhibitory effects are clinically significant at therapeutic doses of TCP (Salsali et al., 2004) . TCP also did not inhibit the dehydration of nimodipine to the pyridine metabolite in human liver microsomes, which is regarded as a CYP3A-related metabolization pathway (Liu et al., 2000) . CYP2E1 in cryopreserved human hepatocytes was inhibited at high TCP concentrations of 10 mM (1.3 mg/ml), CYP2B6 in human liver microsomes at 1-10 mM TCP (0.13-1.3 mg/ml), and alcohol dehydrogenase at 90 mM TCP (12 mg/ml) only (Li et al., 1999; Nirogi et al., 2015; Roig et al., 1991) . A comparison of MAO inhibitors with respect to irreversible inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP2B6 revealed a substantial effect for hydrazine MAO inhibitors, such as phenelzine, but no irreversible inhibition for TCP (Nirogi et al., 2015; Polasek et al., 2006) . In clinical studies, TCP did not influence the plasma concentrations of amitriptyline or carbamazepine in depressed patients who received concomitant TCP therapy (Ketter et al., 1995; Kuss and Ackenheil, 2005) . In addition, plasma concentrations of carbamazepine per dose were more than two times higher in patients with concomitant phenelzine compared to TCP (Barklage et al., 1992) .
CYP2A6 seems to be the only exception to the low inhibition of CYP enzymes by TCP. TCP was found to be a highly specific inhibitor of CYP2A6 with K i =0.08 mM (10 ng/ml). This low K i of racemic TCP was attributed mainly to (+)-TCP (K i =0.05 mM) because a much higher K i =2.0 mM was found for (-)-TCP in a study of the enantiomers (Zhang et al., 2001) . CYP2A6 is regarded as the most important enzyme in the metabolism of nicotine and it has been suggested that the number of cigarettes consumed may be reduced in smokers treated with TCP. On the other hand, CYP2A6 plays a very minor role in the metabolism of drugs, and CYP2A6 inhibition by TCP has therefore only low clinical relevance in terms of drug interactions (Raunio and Rahnasto-Rilla, 2012) . It is added for completeness that also MAO inhibition by TCP may be involved in pharmacokinetic drug interactions. However, only a low number of drugs are affected, e.g. sumatriptan (Dixon et al., 1994) .
In conclusion, a considerable amount of new data shows that therapeutic doses of TCP have a very low potential for inhibiting relevant drug metabolizing enzymes. Therefore, the risk of pharmacokinetic drug interactions with TCP is considered low. This seems to be in contrast to the MAO inhibitors phenelzine and isoniazid and is in clear contrast to the selective serotonin reuptake inhibitors (SSRI) fluoxetine, fluvoxamine, and paroxetine, which may inhibit CYP2C19, CYP2D6, and CYP3A4 at therapeutic doses. More clinical data is needed for a final evaluation on the potential of phenelzine for pharmacokinetic interactions.
3.3. Chronic TCP application in the research of modern targets of depression and animal models of depression Chronic application for 21-28 days of low to medium doses of TCP (mainly 0.5 and 1.0 mg/kg/day, one study 5 mg/kg/day (Ordway et al., 1991) ) in rats decreased the densities of α 2 -adrenoceptors (Greenshaw et al., 1988) , β 1 -and β 2 -adrenoceptors (Ordway et al., 1991; Paetsch and Greenshaw, 1993) , 5-hydroxytryptamine-(5-HT 2 , serotonin)-receptors (Goodnough and Baker, 1994) and dopamine-D 1 -and D 2 -receptors (Paetsch and Greenshaw, 1992) in certain regions of the CNS. This receptor down-regulation is likely a consequence of increased neurotransmitter concentration after acute TCP treatment and may also explain some aspects of the delayed therapeutic effect and tolerance to adverse effects. Receptors of other neurotransmitters have also been investigated, such as GABA receptors (Sands et al., 2004) . However, these results do not support the prevailing amine hypothesis of depression.
According to the neurotrophin hypothesis of depression, chronic TCP application increased the expression of plasticity/ growth-associated factors in the CNS, such as growth associated protein-(GAP)-43 in rat cultured hippocampal cells with 2 mM TCP for 7 days (Chen et al., 2003) . Chronic, but not acute, administration of TCP (10 mg/kg/day for 14 days) significantly increased second messenger cAMP-response-element-(CRE)-mediated gene transcription in mice, which is involved in the regulation of brain-derived neurotrophic factor (BDNF) (Thome et al., 2000) . BDNF itself was also increased with 5-10 mg/kg/ day TCP for 14-21 days (Assareh et al., 2012; Khundakar and Zetterström, 2006; Torregrossa et al., 2005) , including the aging brain (Garza et al., 2004) , in ex-vivo experimental animal (rats) studies. BDNF increase by 7.5 mg/kg/day TCP in rats for 7 days was dependent on the uptake of peripheral insulin-like growth factor-1 (IGF-1) into the CNS (Chen and Russo-Neustadt, 2007) . Therefore, outgrowth of hippocampal dendrites in rat cultured hippocampal cells with 1-50 mM TCP for 10 days (Seo et al., 2014) and ex-vivo bromodeoxyuridine-(BrdU)-labeled neurogenesis in rats with 7.5-10 mg/kg/day TCP for 21 days (Malberg et al., 2000) were increased. 1.5-2 mg/kg/day TCP in rats for 28 days also reduced stress-induced hypersecretion of corticotropin releasing factor (CRF), which is in agreement with the hypothesis of hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in depression (Stout et al., 2002) .
With regard to experimental animal models of depression, acute and chronic TCP was active in behavioral despair at doses of 10 mg/kg (Porsolt, 1981; Wicke et al., 2007) , including 10 mg/kg/ day in rats for 21 days (Torregrossa et al., 2005) , in learned helplessness at doses of 1.25-10 mg/kg/day in rats for 5-8 days (Caille et al., 1996; Takamori et al., 2001) , and in reserpine reversal at doses of 0.5-3 mg/kg in rats (Burkard et al., 1989; Kato et al., 1998) . These data are consistent with studies of other antidepressant drugs, but not for antipsychotics. Nevertheless, there are some differences in the effects of TCP and other antidepressants, but these will not be discussed in detail here at the preclinical level. For example, the SSRIs citalopram and sertraline did not reduce α 2 -adrenoceptor density (Kovachich et al., 1993) . In addition, trazodone did not reduce β-adrenoceptors (Ordway et al., 1991) , and BDNF mRNA regulation was different for TCP and fluoxetine (Dias et al., 2003) . Weber-Grandke et al., 1993) . These limited data are in good agreement with a more recent pharmacokinetic study of the TCP drug preparation Jatrosom s 20 mg in 24 healthy volunteers with c max =61.9717.5 ng/ml (32.5 to 106.9) and t max =1.270.3 h (0.5-1.5) (mean7standard deviation (range)).
In some patients, however, the c max was 144 ng/ml and close to 200 ng/ml after administration of 20 mg (Edwards, 1985; Mallinger and Smith, 1991) . The pharmacokinetic half-life (t 1/2 ) of TCP is approximately 2 h, which is very low compared to most other antidepressant drugs (t 1/2 typically 8-30 h), including phenelzine (t 1/2 =9.8 h) (Hiemke et al., 2011; Kallem et al., 2016) . The c max , t max and t 1/2 after a 20 mg single dose of TCP were found to be independent of the daily dose in patients already treated with 20-50 mg/day for several weeks (Mallinger et al., 1986) . Other authors have reported that the c max during chronic treatment with 10 mg/day TCP was approximately double that in patients receiving a single 10 mg dose without pretreatment of TCP (Mutschler and Möhrke, 1983) . This may be explained by MAO-dependent metabolization of TCP which is active during the first dose only. However, the reports are in agreement with regard to pre-dose trough levels in steady state (i.e., 412 h after the last dose), which are always close to zero (Mallinger et al., 1986 (Mallinger et al., , 1990 Mutschler and Möhrke, 1983) . More studies are needed to clarify the relationship between single dose and multiple dose pharmacokinetics of TCP. Data are also lacking with regard to linear or possibly non-linear pharmacokinetics. As an illustration, theoretical profiles of TCP plasma concentrations calculated with the above data and as applicable to the "mean" TCP patient are shown in Figure 3 for dose schemes used in clinical practice.
Trough plasma concentrations of TCP in steady-state therefore do not represent the plasma concentration curve found over the entire dose interval, as is typical for other antidepressant drugs and which is used in therapeutic drug monitoring (TDM). Moreover, TDM of TCP is also not advised because even complete curves of plasma concentrations with area under the curve (AUC) are not representative of the primary pharmacodynamic effect of irreversible MAO inhibition or, in other words, because of the complete decoupling of pharmacokinetics (very short pharmacokinetic half-life) and pharmacodynamics (very long pharmacodynamic half-life) (Hiemke et al., 2011) . No relationship between plasma concentration and therapeutic effect is expected. If norepinephrine reuptake inhibition or even amine release add to the antidepressant effect of TCP at higher doses, then a relationship between c max or other pharmacokinetic variables with therapeutic effect may be possible. However, this has not been investigated in welldesigned clinical studies with, for instance, fixed doses. Platelet MAO-B levels and treatment response have been investigated over a range of 30-97% MAO inhibition and no relationship was found (Himmelhoch et al., 1991; Mallinger et al., 1990) . This can be explained by the inadequacy of the platelet MAO-B model for determining brain MAO-A/B levels, additional relevant effects of TCP such as noradrenaline reuptake inhibition, or inadequate variable dose design.
Distribution of TCP
Previous experimental animal studies assessing TCP distribution after intraperitoneal application found that the compound is distributed throughout the body, including brain, liver, lung, spleen, heart, and kidneys. The c max in brain was approximately 3 times higher than that in blood. The t max was also faster in brain (30 min), suggesting effective transfer across the blood-brain barrier (Coutts et al., 1987) . In addition, maximum brain levels increased nonlinearly with dose at very high doses of 5-20 mg/kg (Fuentes et al., 1976) .
Metabolism of TCP
Early studies revealed that TCP is excreted in the form of metabolites. Phase-I metabolites found in experimental animals include p-hydroxytranylcypromine, N-acetyltranylcypromine, and N-acetyl-p-hydroxytranylcypromine, which maintain some MAO inhibitor activity but are less potent than the parent drug. Unfortunately, there is very limited data of TCP metabolites in humans and no studies to date have used modern chemical analytical methods to investigate phase-II metabolites of TCP. The main result of human studies is the exclusion of amphetamine as a metabolite of TCP (Baker et al., 1999; Keck et al., 1991) .
Enantiomer pharmacokinetics of TCP
Reliable data have been generated for the differential enantiomer pharmacokinetics of the parent drug after a single dose. In terms of c max and AUC, (-)-TCP accounts to approximately 80-90% of racemic drug with only 10-20% (+ )-TCP present after a 20 mg oral dose of (7)-TCP in humans. The t 1/2 of ( + )-TCP is approximately 0.5 to 1.0 h shorter than that for (-)-TCP (Spahn-Langguth et al., 1992) . No data are available for TCP enantiomers in plasma after multiple doses.
3.4.5. Pharmacokinetic drug interactions of TCP in the direction from other drugs to TCP As summarized in paragraph 3.2 for drug metabolizing enzymes, several new studies have established that TCP does not impair the pharmacokinetics of most drugs. Only very limited data are currently available for the reverse direction of pharmacokinetic interactions (i.e., plasma levels of TCP influenced by comedication). An experimental pharmacokinetic study in healthy volunteers found that 30 mg paroxetine, which is a strong CYP2D6 inhibitor, did not change plasma concentrations of TCP (note the strict contraindication of this combination in patients due to a pharmacodynamic interaction; see below). CYP2D6 has been excluded therefore as an important drug metabolizing enzyme of TCP (Dechant and Clissold, 1991) . For comparison, plasma concentrations of tricyclic antidepressants did increase 5-to 10-fold in similar studies with paroxetine (Kaye et al., 1989) . Iprindole, a second generation tricyclic antidepressant that has not reached wide clinical application, as well as chlorpromazine and trifluoperazine were found to increase TCP levels in rat brain and liver tissues, which was attributed to inhibition of ring hydroxylation (Aspeslet et al., 1992; Baker et al., 1986) . Interpretation of these few results is difficult. More studies including studies in healthy volunteers and patients are needed.
3.5. Pharmacodynamic drug interactions and allowed drug combinations 3.5.1. Drugs discussed mainly with respect to the risk of severe serotonin toxicity (SST) Serotonin toxicity as defined according to the Hunter Serotonin Toxicity Criteria by clonus, agitation, diaphoresis, tremor and hyperreflexia as well as hypertonicity and maximum temperature 438 1C in severe cases (severe serotonin toxicity, SST) must be recognized as the most dangerous drug interaction of TCP. In contrast to moderate serotonin toxicity which affects about 15% of SSRI overdoses, SST has been found only in drug interactions of two serotonergic activating drugs (Dunkley et al., 2003; Gillman, 2006) . 3.5.1.1. Antidepressants: SSRIs, SSNRIs, clomipramine, imipramine, L-tryptophan. Serotonergic activating drugs have the risk of inducing life-threatening SST, which has led to a strict contraindication of SSRIs, selective serotonin norepinephrine reuptake inhibitors (SSNRIs), two serotonergic tri-or tetracyclic antidepressants (TCAs) (clomipramine and imipramine), and the serotonin precursor L-tryptophan (Gillman, 2006) . Several cases of moderate serotonin toxicity or SST have been reported in patients receiving TCP, including a fatal outcome, and in some cases after a single dose of a serotonin reuptake inhibitor (Bhatara and Bandettini, 1993; Brubacher et al., 1996; Feighner et al., 1990; Otte et al., 2003; Tackley and Tregaskis, 1987) . In a more recent case, a patient was taking TCP together with an SSRI even with the intention of committing suicide (Degner et al., 2010) . The serotonin reuptake inhibition of some analgesic (pethidin, tramadol) and antitussive (dextromethorphan) opioids has to be considered as well and leads to a contraindication (Gillman, 2005) . 3.5.1.2. Antidepressants: other TCAs. Non-or lowserotonergic activating TCAs and 5-HT 2A antagonists, such as amitriptyline, doxepin, and mianserin as well as trazodone have been found to be safe in this regard at low to moderate doses. Retrospective chart reviews of amitriptyline in combination with TCP in 37 and 10 patients Figure 3 Theoretical profiles of tranylcypromine plasma concentrations in common clinical dose schemes: three 20 mg doses (solid line), a 40 mg dose and a 20 mg dose (dashed line), taken in intervals of four hours, and a single 60 mg dose (dotted line); The profiles were calculated according to a hypothetical one compartment model with parameters fitting mean values of pharmacokinetic studies of tranylcypromine, i.e. bioavailability f =0.5, volume of distribution V=1.75 l/kg, body weight m =75 kg, absorption rate constant k a = 3 h À 1 and elimination rate constant k e =0.3465 h À 1 (corresponding to t 1/2 =2 h). (Schmauss et al., 1988; Schuckit et al., 1971) , doxepin in 55 and 4 patients (Ayd, 1973; Schmauss et al., 1988) and trazodone in 13 and 7 patients (Nierenberg and Keck, 1989; Thomas et al., 2015) , respectively, have been published. Prospective open clinical studies of mianserin (n= 39) (Graham, 1988) , trazodone (n =21) (Jacobsen, 1990) , and randomized controlled studies of amitriptyline with 10, 20, and 25 patients, respectively, in the combination group (O'Brien et al., 1993; Razani et al., 1983; White et al., 1980) have also been conducted and confirmed acceptable tolerability of the combinations. Moreover, these antidepressants have not shown toxicities when combined with TCP if they are started together with or before TCP (i.e., excluding a sequence of TCA added to a course of TCP and excluding intravenous TCAs) (Thomas et al., 2015; White and Simpson, 1981) . Taking into account also a published statement that thousands of patients were treated with the allowed, i.e. not strictly contraindicated, TCP-TCA combinations (White and Simpson, 1981) , the data set is regarded as sufficient for safe trials of these TCP-TCA combinations in selected patients with treatment resistant depression (TRD). More recently, an acceptable safety of some TCA combinations with TCP in the context of TRD has also been confirmed in two new reviews of the subject including a detailed discussion of in-vitro preclinical data. The allowed TCAs and associated metabolites display low serotonin reuptake inhibition compared to norepinephrine reuptake inhibition (Gillman 2006 (Gillman , 2007 . In addition to lower serotonin reuptake inhibition, they also display considerable 5-HT 2A antagonism relative to serotonin reuptake inhibition with lower ratios of inhibition constants K i (5-HT 2A antagonism) per K i (5-HT-reuptake inhibition at SERT) of 1.45 (amitriptyline) and 0.38 (doxepin) compared to 11.4 (imipramine) and 250 (clomipramine) (Gillman, 2007) . Low ratios of K i of 5-HT 2A antagonism to serotonin reuptake inhibition are discussed regarding a protective effect, since the most severe and life-threatening symptom, hyperthermia, is mediated by this receptor (Shioda et al., 2010) . Trimipramine may be added to the TCAs not strictly contraindicated with TCP because of the special receptor pharmacology without serotonin reuptake inhibition (Berger and Gastpar, 1996) and clinical safety data package when combined with other MAO inhibitors (White and Simpson, 1981) , despite limited clinical data published for TCP with trimipramine (Adli et al., 2008; Ray, 1973) . Nortriptyline is also regarded as having a very low serotonergic risk; however, no published clinical data have been found and the combination of two stimulatory antidepressants may be misleading. Furthermore, no published clinical data are available for mirtazapine in combination with TCP and the discussion is controversial in the perspective of other antidepressant combinations with mirtazapine and SST. A review of the clinical pharmacology of SST and moderate serotonin toxicity concluded that mirtazapine is unable to induce SST when combined with MAO inhibitors (Gillman, 2006) . A more recent study showed that mirtazapine by 5-HT 2A antagonism did even abolish hyperthermia as the most dangerous symptom in a TCP-fluoxetine animal model of SST (Shioda et al., 2010) . TCP has been combined or augmented successfully with other psychopharmaceuticals that do not activate serotonergic pathways, such as bupropion (n=2, n=1 and n=unknown, respectively) (Cole and Bodkin, 2002; Quante and Zeugmann, 2012; Pierre and Gitlin, 2000) , tianeptine (n=1) (Tobe, 2012) , and N-acetylcysteine (n=2) (Carvalho et al., 2013) .
3.5.1.3. H 1 Antihistamines and triptanes. A warning for combining H 1 antihistamines with TCP may be limited to a few of the older substances because of their serotonin reuptake inhibition properties, including brompheniramine, chlorpheniramine, and pheniramine (Gillman, 2006; Sinclair, 1972) . Conditions with increased histamine from endogenous sources as treated with H 1 antihistamines are not influenced by TCP (Allen and Rand, 1969) .
A strict contraindication of triptanes with other serotonergic drugs has been questioned in a more detailed survey showing that triptanes are 5-HT 1B/1D agonists, but SST induction requires 5-HT 2A activation (Gillman, 2010) . However, no clinical data are available regarding the combination of TCP with triptanes.
3.5.2. Other psychopharmaceuticals 3.5.2.1. Antipsychotics. First generation antipsychotic drugs have widely been used together with TCP as described in several controlled studies (Barsa and Saunders, 1962; Buffaloe and Sandifer, 1961; Bucci, 1969 Bucci, , 1987 Hedberg et al., 1971; Hordern et al., 1962; Kruse, 1960; Mena et al., 1964; Schiele et al., 1963; Singh and Free, 1960; Vogt, 1961) . A fixed combination of 10 mg TCP with 1 mg trifluoperazine was even available as recently as 1990, but was then withdrawn from the market due to formal regulatory restrictions. Published chart reviews and case reports of second generation antipsychotic drugs in combination with TCP suggest that safety and good tolerability of TCP with antipsychotics may be extended to the entire drug group for the majority of patients (Adli et al., 2008; Goforth and Carroll, 2007; Harms et al., 2000; Koerhuis et al., 2008; Roesch-Ely et al., 2011; Stoll and Haura, 2000) . SST was reported in one patient on TCP with ziprasidone, which is known to exhibit serotonin reuptake inhibition properties (Rim and Gitlin, 2010) . However, similar cases were also observed for the combination of second generation antipsychotics with SSRI (Karki and Masood, 2003) . 3.5.2.2. Benzodiazepines. Benzodiazepines (Adli et al., 2008; Birkenhäger et al., 2004; Himmelhoch et al., 1982; Nolen et al., 1985 Nolen et al., , 1988 Nolen et al., , 1993 O'Brien et al., 1993; Thomas et al., 2015; Volz et al., 1994b) and hypnotics or sedatives not otherwise specified (Heinze et al., 1993; Volz et al., 1994a; White et al., 1984) have been widely used as a comedication with TCP in controlled clinical studies and in clinical practice. Less data are available for zopiclone and zolpidem (Adli et al., 2008; Thomas et al., 2015) ; however, these modern hypnotics may also be safe because of the very similar mechanism of action as benzodiazepines. No case reports suspecting severe drug interactions of benzodiazepines or other hypnosedatives with TCP have been published to date. 3.5.2.3. Mood stabilizers. Anecdotic reports and three case series of 12, 13, and 25 patients, respectively, have been published on TCP augmentation with lithium, or TCP added to lithium, which comprised the safety and successful treatment of patients (Adli et al., 2008; Barker and Eccleston, 1984; Freilich and Bennett, 1983; Himmelhoch et al., 1972; Ketter et al., 1995; Mallinger et al., 2009; Mittmann et al., 1999; Price et al., 1985; Tariot et al., 1986) . Follow-up of nonresponders to TCP in a controlled study resulted in four responders (80%) to lithium augmentation of TCP (Nolen et al., 1993) . Lithium was also allowed as comedication in a controlled study of TCP in bipolar depression, which was administered to 6 patients (Nolen et al., 2007) . There have also been smaller case series published (total n= 14-18) of safe and successful treatment of TCP with carbamazepine and no reports of adverse effects have been observed with this combination (Adli et al., 2008; Barklage et al., 1992; Joffe et al., 1985; Ketter et al., 1995; Lydiard et al., 1987) . Surprisingly, TCP is contraindicated in the summaries of product characteristics of carbamazepine drug products. Valproate, lamotrigine, and gabapentin in combination with TCP received no special comment in some reports (Adli et al., 2008; Mallinger et al., 2009; Thomas et al., 2015) .
Direct and indirect sympathomimetics
Amphetamines and other indirect sympathomimetics (neurotransmitter releasers, mainly releasing norepinephrine), such as ephedrine, amezinium methylsulfate, phenylpropanolamine, cathine, amfepramone, and metamfepramone used in over-the-counter cold remedies, anorectics, and antihypotensives have a high risk of life-threatening hypertensive crises and central neurotoxicity if taken concomitantly with TCP (Cuthbert et al., 1969, Cuthbert and Vere, 1971; Dawson et al., 1995; Harrison et al., 1989) . Education of the patient and cooperation with pharmacies and other physicians is needed to ensure compliance. In contrast, low doses of direct sympathomimetics, such as epinephrine, norepinephrine, etilefrine, xylometazoline, and tramazoline that are used in local anesthetics, antihypotensives, and nose drops/sprays are regarded as relatively safe (Boakes et al., 1973; Thompson et al., 1997) .
Levodopa and T3/T4
Pure levodopa drugs have a risk of peripheral hyperdopaminergic reactions; however, the fixed combinations with decarboxylase inhibitors used today may be coadministered with TCP (Hargrave and Ashford, 1992; Teychenne et al., 1975) . Despite reported therapeutic success in selected patients (n = 1) (Bauer et al., 1998) , high doses of triiodthyronine (T3) and levothyroxine (T4) such as 300 mg/day T4 may include the risk of drug interactions in the cardiovascular system (Köberle et al., 2011) , which is why a euthyroid status should be maintained in T3/T4-augmentation of TCP.
Taken together, these findings indicate that controlled polypharmacy may be considered with TCP in the treatment of TRD after failed trials with other treatments, including TCP monotherapy. Trials of alternative monotherapies may be preferred whenever advised. More published data are needed for the combination of TCP with various agents due to inadequate support for safety.
Food interaction of tranylcypromine with tyramine
Tyramine is a strong indirect sympathomimetic agent that induces the release of norepinephrine enriched in synaptic vesicles and, thereby, precipitates life-threatening hypertensive crisis accompanied by severe headache, chest tightness, pallor, nausea, and sweating ("cheese reaction"). The presence of tyramine, a substrate of MAO-A and MAO-B, in food is not a risk for the normal population because of sufficient MAO activity in gut and liver and a tyramine tolerance of 800-2000 mg per meal. With irreversible MAO-A/B inhibition by TCP, however, the presence of only 35 mg of tyramine in food (range 20-50 mg) was found to increase systolic blood pressure by 30 mmHg in a preselected population most sensitive to tyramine. An amount of 25 mg tyramine per meal is therefore regarded as a safety margin for severe reactions and 6 mg as a conservative threshold for the initiation of mild symptoms (Berlin et al., 1989; Gillman, 2011) . According to recent invitro studies, extensive and ultra-rapid metabolizers of CYP2D6 may be expected to be less sensitive to a tyramine hypertensive reaction than intermediate and poor metabolizers because a considerable portion of tyramine metabolism was found to be CYP2D6 dependent, but not MAO-dependent. However, dopamine, which is the metabolite of tyramine in this pathway, exerts its own hypertensive effect, although to a lesser extent than tyramine (Niwa et al., 2011) . The role of SSAOs in human tyramine metabolism has not been clarified. It was shown that tyramine can be metabolized by some nonhuman SSAOs (Ochiai et al., 2006) . Reversible and selective MAO-A inhibition by moclobemide leaves sufficient MAO activity in liver and gut without substantial impairment of the safety margin for tyramine in food (Berlin et al., 1989; Burkard et al., 1989) .
Tyramine restricted diet during treatment with TCP and an evaluation of the risk of tyramine induced hypertensive crisis is provided in part II of the review.
Toxicity of TCP in acute overdose
In an attempt to compare antidepressant drugs, a calculation of the safety factor of TCP according to the quotient of lethal dose LD 50 of 75 mg/kg (oral, rats), a therapeutic dose of 20-40 mg in humans, and a body weight of 70 kg yields a value of 131-262, indicating that the lethal dose in small animals is 131-to 262-fold of the therapeutic dose. Safety factors of amitriptyline and imipramine were calculated as 106 and 135 and those of fluoxetine and paroxetine were 904 and 748 (Kelvin and Hakansson, 1989) . The acute toxicity of TCP is therefore expected to be similar to that of TCAs and higher than that for SSRIs.
In a retrospective study of intoxications over 5 years (1987) (1988) (1989) (1990) (1991) (1992) , TCP was listed as number 8 of 26 antidepressants where 28 patients died per 1 million prescriptions of TCP, and as a number 12 of 26 where 0.54 patients died per 1 million defined daily doses (DDD) of TCP. TCAs were more toxic and SSRIs were less toxic in this study, which is in agreement with the above calculation (Henry et al., 1995) . A similar study conducted on patients treated in Vienna from 1991 to 1997 found no lethal intoxications with TCP; however, decreased use of TCP has to be considered in this decade (Frey et al., 2000) .
Twenty cases of acute overdose after mainly suicidal intent (90%), including 10 fatalities, have been recently summarized in a comprehensive review of TCP intoxications (Gahr et al., 2013) . Intoxication symptoms included disturbance of consciousness, cardiovascular, hyperthermia, respiratory distress, delirium, muscular rigidity, and renal failure. The highest dose administered where the patient survived was 4000 mg and the lowest fatal dose was 170 mg, which is explained by the crucial role that individual factors play in some outliers. The mean survived and lethal doses of 484 mg and 849 mg, respectively, may provide a more useful view on the clinical toxicity of TCP. This constitutes a clinical safety factor of approximately 10 as the quotient of mean survived dose and therapeutic dose of 40-60 mg/day.
Conclusion
Despite numerous studies on TCP have been conducted during the last 25 years, including studies using it as a reference for new antidepressants, some areas of the pharmacology of TCP are still incompletely described according to modern standards. On the other hand, clinical data of TCP accumulated over more than five decades have added important information to close this gap. In summary, TCP as an irreversible and nonselective MAO-A/B inhibitor is directed to a pharmacological target receiving increased attention today. TCP is very different in this regard to the majority of antidepressant drugs which act by neurotransmitter reuptake inhibition. An altered MAO enzyme inhibition kinetics compared to reversible MAO inhibition, and decoupling between pharmacokinetics and pharmacodynamics because of the irreversible primary mechanism of action complete these basic differences. Additional norepinephrine reuptake inhibition and low propensity to pharmacokinetic interactions of TCP are properties marking a difference within the drug group of irreversible MAO-A/B inhibitors. TCP is active in all relevant animal models and other targets of preclinical depression research. With regard to safety pharmacology, relative tyramine incompatibility and drug interactions with serotonin activating drugs and indirect sympathomimetics attract most attention. A novel research area of TCP pharmacology comprises the new target lysine-specific demethylase 1 (LSD1) with studies of epigenome-modifying activities e.g. in cancer models. More studies are needed to better describe the pharmacology of TCP, for example the role of norepinephrine reuptake inhibition, linearity of pharmacokinetics, quantitative data of metabolites, interaction with P-glycoprotein, and in-vivo MAO occupancy in human brain after TCP including MAO recovery.
The pharmacological properties summarized in this review part I (Table 3) imply that specific components have to be considered in the evaluation of the benefit-risk ratio of TCP compared with the majority of antidepressants used today, and that different clinical properties are also expected. The clinical data of TCP and an evaluation of benefit-risk ratio are provided in part II of the review.
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